Covid 19 Research using Clinical Trials (Home Page)
Report for D003072: Cognition Disorders NIH
(Synonyms: Cognit, Cogniti, Cognitio, Cognition Disor, Cognition Disorder, Cognition Disorders)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (8)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug568 | COVID-19 swap test PCR Wiki | 0.71 |
| drug1797 | Muse headband with Myndlift app Wiki | 0.71 |
| drug1486 | Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment Wiki | 0.71 |
| drug1185 | Goal Management Training (GMT) Wiki | 0.71 |
| drug924 | Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment Wiki | 0.71 |
| drug922 | Doxycycline Wiki | 0.35 |
| drug2730 | Standard treatment Wiki | 0.29 |
| drug2122 | Placebo Wiki | 0.04 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004827 | Epilepsy NIH | 0.71 |
| D012640 | Seizures NIH | 0.50 |
| D060825 | Cognitive Dysfunction NIH | 0.45 |
| D009422 | Nervous System Diseases NIH | 0.41 |
| D020521 | Stroke NIH | 0.20 |
| D040921 | Stress Disorders, Traumatic NIH | 0.14 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.13 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001268 | Mental deterioration HPO | 0.45 |
| HP:0001250 | Seizure HPO | 0.41 |
| HP:0001297 | Stroke HPO | 0.20 |
There are 2 clinical trials
Clinical Trials
1 COVID-19 Prevalence, Morbidity and Long Term Cognitive Deficits in Consecutive Patients Presenting With Acute Neurological Symptoms
The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
NCT04377425 Neurological Diseases or Conditions Stroke, Acute Seizure Disorder Diagnostic Test: COVID-19 swap test PCR MeSH:Stroke Seizures Epilepsy Cognition Disorders Cognitive Dysfunction Nervous System Diseases
HPO:Bilateral tonic-clonic seizure Cognitive impairment Focal sensory seizure Focal-onset seizure Generalized-onset seizure Mental deterioration Seizure Stroke
Primary Outcomes
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 months
Secondary Outcomes
Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 months
Description: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 months
Description: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 months
Description: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 months
Description: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 months
Description: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 months
2 A Randomized Control Trial Examining the Treatment Efficacy of a Novel Approach to Cognitive Remediation in Individuals With Post-Traumatic Stress Disorder and Co-Morbid Conditions
Primary Outcomes
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsSecondary Outcomes
Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 monthsThis study will evaluate the effect of a manualized treatment (Goal Management Training, or GMT) on the cognitive impairments associated with PTSD (Post-Traumatic Stress Disorder) in certain populations. Participants will be randomized to either GMT group treatment (with or without use of a mindfulness meditation aid), or a wait-list condition.
NCT04457271 PTSD Post-traumatic Stress Disorder Cognitive Impairment Cognitive Dysfunction Cognitive Deficit Behavioral: Goal Management Training (GMT) Device: Muse headband with Myndlift app MeSH:Cognitive Dysfunction Stress Disorders, Traumatic Stress Disorders, Post-Traumatic Cognition Disorders
HPO:Cognitive impairment Mental deterioration
Primary Outcomes
Description: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.
Measure: Change in Sustained Attention to Response Task (SART) scores from baseline to post-treatment assessment Time: 9 weeks
Description: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.
Measure: Change in Sustained Attention to Response Task (SART) scores from post-treatment to 3-month follow-up assessment Time: 12 weeks
Description: Assesses the participant's ability to act with forethought, and sequence behaviour in an orderly fashion to reach specific goals (i.e., executive functioning). Similar to the Tower of London test.
Measure: Change in score on Spatial Planning task (part of Cambridge Brain Science's online battery) from baseline to post-treatment assessment. Time: 9 weeks
Description: Assesses the participant's ability to act with forethought, and sequence behaviour in an orderly fashion to reach specific goals (i.e., executive functioning). Similar to the Tower of London test.
Measure: Change in score on Spatial Planning task (part of Cambridge Brain Science's online battery) from post-treatment to 3-month follow-up assessment. Time: 12 weeks
Description: A 36-item self-report measure that assesses difficulties with emotion regulation across six domains. A total score is derived by summing all the items - ranging from 36 to 180. Higher scores indicate greater dysfunction in emotion regulation.
Measure: Change in Difficulties in Emotion Regulation Scale (DERS) score from baseline to post-treatment assessment Time: 9 weeks
Description: A 36-item self-report measure that assesses difficulties with emotion regulation across six domains. A total score is derived by summing all the items - ranging from 36 to 180. Higher scores indicate greater dysfunction in emotion regulation.
Measure: Change in Difficulties in Emotion Regulation Scale (DERS) score from post-treatment to 3-month follow-up assessment Time: 12 weeks
Description: Gold standard, clinician administered PTSD assessment tool; min. score=0, max=80, with higher scores representing greater PTSD symptoms
Measure: Change in Clinician Administered PTSD Scale (CAPS) score from baseline to post-treatment assessment Time: 9 weeks
Description: Gold standard, clinician administered PTSD assessment tool; min. score=0, max=80, with higher scores representing greater PTSD symptoms
Measure: Change in Clinician Administered PTSD Scale (CAPS) score from post-treatment to 3-month follow-up assessment Time: 12 weeks
HPO Nodes
Primary Outcomes
Description: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.
Measure: Change in Sustained Attention to Response Task (SART) scores from baseline to post-treatment assessment Time: 9 weeksDescription: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.
Measure: Change in Sustained Attention to Response Task (SART) scores from post-treatment to 3-month follow-up assessment Time: 12 weeksDescription: Assesses the participant's ability to act with forethought, and sequence behaviour in an orderly fashion to reach specific goals (i.e., executive functioning). Similar to the Tower of London test.
Measure: Change in score on Spatial Planning task (part of Cambridge Brain Science's online battery) from baseline to post-treatment assessment. Time: 9 weeksDescription: Assesses the participant's ability to act with forethought, and sequence behaviour in an orderly fashion to reach specific goals (i.e., executive functioning). Similar to the Tower of London test.
Measure: Change in score on Spatial Planning task (part of Cambridge Brain Science's online battery) from post-treatment to 3-month follow-up assessment. Time: 12 weeksDescription: A 36-item self-report measure that assesses difficulties with emotion regulation across six domains. A total score is derived by summing all the items - ranging from 36 to 180. Higher scores indicate greater dysfunction in emotion regulation.
Measure: Change in Difficulties in Emotion Regulation Scale (DERS) score from baseline to post-treatment assessment Time: 9 weeksDescription: A 36-item self-report measure that assesses difficulties with emotion regulation across six domains. A total score is derived by summing all the items - ranging from 36 to 180. Higher scores indicate greater dysfunction in emotion regulation.
Measure: Change in Difficulties in Emotion Regulation Scale (DERS) score from post-treatment to 3-month follow-up assessment Time: 12 weeksDescription: Gold standard, clinician administered PTSD assessment tool; min. score=0, max=80, with higher scores representing greater PTSD symptoms
Measure: Change in Clinician Administered PTSD Scale (CAPS) score from baseline to post-treatment assessment Time: 9 weeksDescription: Gold standard, clinician administered PTSD assessment tool; min. score=0, max=80, with higher scores representing greater PTSD symptoms
Measure: Change in Clinician Administered PTSD Scale (CAPS) score from post-treatment to 3-month follow-up assessment Time: 12 weeks